Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2019.1648430
Abstract: ABSTRACT Introduction: A PEGylated form of irinotecan, a topoisomerase I inhibitor, is now available in commerce; its safety and efficacy have been tested in platinum resistant/refractory ovarian cancer (PROC) patients. This novel agent is known… read more here.
Keywords: etirinotecan pegol; ovarian cancer; refractory ovarian; platinum resistant ... See more keywords
Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2019.00180
Abstract: Targeted radiopharmaceuticals for therapeutic use deliver radionuclides directly to tumor anywhere in the body, and therefore, have renewed interest for clinical development in women with disseminated chemorefractory ovarian cancers. About two in every five women… read more here.
Keywords: relapsed refractory; phase; ovarian cancers; ovarian cancer ... See more keywords